ジョージア州における統合失調症の臨床試験
ジョージア州内の拠点で、統合失調症に関する29件の研究が参加者を募集しています。
ジョージア州内の都市
公式研究テキスト（英語）
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
- Vanda Investigational Site, Atlanta
- Vanda Investigational Site, Atlanta
- Vanda Investigational Site, Decatur
被験者募集中第4相
12歳〜17歳 · 全性別 · 2026/10/01更新 · NCT05648591A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
- Synexus Clinical Research US Inc, Atlanta
被験者募集中第1相
18歳〜55歳 · 全性別 · 2026/09/28更新 · NCT07615426Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Atlanta Center for Medical Research, Atlanta
- Local Institution - 0070, Sandy Springs
- Local Institution - 0189, Savannah
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/09/28更新 · NCT07686263NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Site, Atlanta
- Neurocrine Clinical Site, Atlanta
- Neurocrine Clinical Site, Decatur
- 他1件
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/09/25更新 · NCT07114874Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
- Neurocrine Clinical Site, Atlanta
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/09/25更新 · NCT07227818Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- CenExeli Research LLC, Atlanta
- Atlanta Center for Medical Research, Atlanta
- CenExeli Research LLC 1, Savannah
被験者募集中第3相
5歳〜17歳 · 全性別 · 2026/09/25更新 · NCT06229210A Study of Brenipatide in Adult Participants With Schizophrenia
- Atlanta Center for Medical Research, Atlanta
- Augusta University, Augusta
被験者募集中第2相
18歳〜55歳 · 全性別 · 2026/09/22更新 · NCT07410507A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Atlanta Center for Medical Research, Atlanta
- Salveo Integrative Health - Lawrenceville, Lawrenceville
- Denali Health Atlanta, LLC, Stone Mountain
被験者募集中第3相
5歳〜17歳 · 全性別 · 2026/09/22更新 · NCT07424404A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Augusta
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/18更新 · NCT07105111A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
- CenExel iResearch, LLC, Decatur
被験者募集中第1相
18歳〜55歳 · 全性別 · 2026/09/17更新 · NCT0773449352-week Open Label Safety-Tolerability Study
- CenExel, Atlanta
- Accelerated Clinical Trial, Snellville
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/09/09更新 · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Atlanta Center for Medical Research, Atlanta
- Salveo Integrative Health - Lawrenceville, Lawrenceville
- Denali Health Atlanta, LLC, Stone Mountain
被験者募集中第3相
13歳〜17歳 · 全性別 · 2026/09/04更新 · NCT07288567A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
- Atlanta Center for Medical Research, Atlanta
- CenExel iResearch, LLC, Decatur
被験者募集中第1相
18歳〜55歳 · 全性別 · 2026/09/02更新 · NCT07061288A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, Atlanta
- Clinical Site, Decatur
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/09/01更新 · NCT07459647Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Emory University., Atlanta
- Local Institution - 0049, Austell
- Local Institution - 0044, Marietta
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/19更新 · NCT07379827Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Alkermes Investigator Site, Decatur
被験者募集中第3相
10歳〜17歳 · 全性別 · 2026/08/14更新 · NCT05303064Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
- Bioxcel Clinical Research Site, Decatur
被験者募集中第1相
10歳〜17歳 · 全性別 · 2026/08/11更新 · NCT05025605Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
- CenExel iResearch, Decatur
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/07/29更新 · NCT07467993Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
- Accelerated Clinical Trial, Snellville
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/07/27更新 · NCT07363577A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Cenexel ACMR, Atlanta
- Cenexel iResearch Atlanta, Decatur
被験者募集中第2相
18歳〜55歳 · 全性別 · 2026/06/23更新 · NCT07191483Anti-Inflammatory Challenge in Schizophrenia
- Grady Memorial Hospital, Atlanta
- Emory University Hospital, Atlanta
被験者募集中第4相
18歳〜55歳 · 全性別 · 2026/06/03更新 · NCT05823532CLOZAPINE Response in Biotype-1
- University of Georgia, Athens
被験者募集中第4相
18歳〜60歳 · 全性別 · 2026/05/11更新 · NCT04580134Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
- Augusta University Research Institute, Inc., Augusta
被験者募集中第4相
18歳〜65歳 · 全性別 · 2026/05/04更新 · NCT05208190Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- University of Georgia, Athens
被験者募集中観察研究
18歳〜40歳 · 全性別 · 2026/03/10更新 · NCT06740383NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, Atlanta
- Neurocrine Clinical Site, Decatur
- Neurocrine Clinical Site, Snellville
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/03/06更新 · NCT06963034Randomized Withdrawal Study in Patients With Schizophrenia
- Vanda Investigational Site, Atlanta
- Vanda Investigational Site, Peachtree Corners
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/01/12更新 · NCT06961968Study of ALTO-101 in Patients With Schizophrenia
- Site 5064, Snellville
被験者募集中第2相
21歳〜55歳 · 全性別 · 2025/12/26更新 · NCT06502964Cognitive Training for Emotion Regulation in Psychotic Disorders
- University of Georgia, Athens
被験者募集中
18歳〜60歳 · 全性別 · 2025/02/05更新 · NCT04414215Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- Reviva site, Atlanta
- Reviva site, Decatur
被験者募集中第3相健康なボランティア歓迎
18歳〜65歳 · 全性別 · 2024/12/19更新 · NCT05184335ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。